SWX:NOVNPharmaceuticals
Novartis (SWX:NOVN) Is Buying Myricx Bio For Up To $1.5 Billion
Novartis (SWX:NOVN) has agreed to acquire UK based Myricx Bio, a privately held biotechnology company.
Myricx Bio focuses on first in class N myristoyltransferase inhibitor (NMTi) antibody drug conjugate technology for cancer treatment.
The deal adds a platform targeting HER2 and B7 H3 positive cancers, including certain treatment resistant tumors, to Novartis' oncology pipeline.
For investors tracking large cap pharma, this move expands how Novartis is positioned within oncology, an area...